19 filings
8-K
PRNB
Principia Biopharma Inc.
9 Dec 19
Principia Presents Consistent Positive Data of PRN1008
6:09am
8-K
PRNB
Principia Biopharma Inc.
5 Nov 19
Principia Biopharma Reports Third Quarter Financial Results
4:10pm
8-K
PRNB
Principia Biopharma Inc.
18 Oct 19
Entry into a Material Definitive Agreement
4:14pm
8-K
PRNB
Principia Biopharma Inc.
15 Oct 19
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
7:09am
8-K
PRNB
Principia Biopharma Inc.
10 Oct 19
Principia Announces Positive Preliminary Data of PRN1008 from its
7:00am
8-K
6mmbxt 8y26
30 Aug 19
Departure of Directors or Certain Officers
4:10pm
8-K
1djmw6xd0 43s9q3
8 Aug 19
Principia Biopharma Reports Second Quarter Financial Results
4:11pm
8-K
j8r08n92 q64w
14 Jun 19
Departure of Directors or Certain Officers
4:05pm
8-K
6aqbh0v ws2c
15 May 19
Principia Biopharma Announces First Patient Dosed in Sanofi’s Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone
9:01am
8-K
6qha4pgvq2 rg3ud7dt
14 May 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:05pm
8-K
3mbbj0yujfctgvku
7 May 19
Principia Biopharma Reports First Quarter Financial Results
4:05pm
8-K
esewuaa9k51ga1z ffi
22 Apr 19
Material Modifications to Rights of Security Holders
4:05pm
8-K
k6ut ltocq
26 Mar 19
Other Events
4:58pm
8-K
mvsanc 4sppfu7c
19 Mar 19
Principia Biopharma Reports Fourth Quarter and Full Year 2018 Financial Results
4:10pm
8-K
8o40hfr4vaw47wz
13 Mar 19
Termination of a Material Definitive Agreement
1:19pm
8-K
pdcc9k
4 Mar 19
Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating
2:25pm
8-K
kg52i0 yrc
28 Feb 19
Other Events
3:26pm
8-K
i27q7
19 Feb 19
Departure of Directors or Certain Officers
5:09pm
8-K
l5uszyoqcsxdhzuj12i
4 Feb 19
Other Events
5:00pm
- Prev
- 1
- Next